A private equity firm that manages $40 billion ($40 billion: more than the GDP of 70 countries) in equity capital deliberately engineered a plan to seize control of over half the U.S. market for coatings that keep life-saving medical devices from shredding your arteries, and its own internal documents prove it.

The Invisible Ingredient That Keeps You Alive During Surgery

When a doctor threads a catheter through the artery in your groin, up through your torso, and into your heart or brain, the only thing preventing that thin plastic tube from scraping and tearing the inside of your blood vessels is a microscopic chemical layer called a hydrophilic coating. Without it, friction from the device would damage vital structures inside your body. The coating makes the device slippery enough to navigate safely through the tight, fragile confines of your vascular system.

These coatings are used on catheters, guidewires, sheaths, and stents. They are deployed in neurovascular procedures (inside your brain), structural heart procedures, coronary procedures, and peripheral vascular procedures. The FDA evaluates hydrophilic coatings as part of every medical device approval; a failed coating can set a device company back millions of dollars and multiple years.

The performance of a hydrophilic coating turns on three measurable criteria: lubricity (how slippery it makes the device), particulate count (how many coating particles shed off inside your body during use), and durability (how long the coating maintains its performance). When coating particles shed inside a patient, it is a patient safety crisis. This is not an abstract engineering concern; it is a matter of who gets hurt on the table.

“Without a hydrophilic coating, excessive friction created by the medical device’s movement could damage vital structures within the patient.” — FTC Amended Complaint, May 14, 2025

Most OEMs (the companies that actually design and manufacture the medical devices you and your family rely on) do not make their own coatings. The chemistry is too complex, the research takes years and costs millions, and the FDA regulatory requirements are strict. So they buy coatings from specialized third-party suppliers. Two companies dominate that supplier market: Surmodics and Biocoat. And as of 2022, a private equity firm named GTCR quietly started buying both of them.

Once A Coating Gets FDA Approval, It’s Locked In Forever

Here is the detail that makes this monopoly play so predatory. When the FDA approves a medical device, it approves the complete device, including whatever specific hydrophilic coating was used in testing. That coating is baked into the regulatory approval. If a medical device manufacturer later wants to switch to a different coating, they must restart the entire FDA approval process from scratch, including fresh development, fresh testing, and a brand-new application.

This creates a structural lock-in that makes the coating supplier extraordinarily powerful. Once your coating provider is chosen and the device goes to market, you are essentially captive to that supplier for the entire commercial lifetime of the device, which can be over a decade. A monopolist who controls the coating market does not just set the price today. They set it for the next ten-plus years on every device currently on the market.

The FTC notes that demand for outsourced hydrophilic coatings is expected to grow as the FDA tightens performance requirements, particularly around particulate count. This is a market getting bigger, more regulated, and more critical to patient safety. GTCR saw that growth curve and decided to own all of it.

The $627 Million Takeover Plan, Written Down In Their Own Documents

GTCR, LLC is a private equity firm founded in 1980 and headquartered in Chicago. It manages $40 billion ($40 billion: enough to give every single teacher in the United States a $50,000 raise for over five years) in equity capital and owns a portfolio spanning medical technology, pharmaceuticals, financial services, media, and telecommunications. Since 2000, GTCR has invested in approximately 125 portfolio companies. This is a firm that knows exactly what it is doing.

On November 2, 2022, GTCR announced it had made a majority investment in Biocoat, Inc., the second-largest hydrophilic coating provider in the United States, founded in 1991 and based in Horsham, Pennsylvania. Then, pursuant to a merger agreement dated May 28, 2024, GTCR agreed to acquire Surmodics, the largest hydrophilic coating provider in the country, at $43 per share, for a total valuation of approximately $627 million ($627 million: enough to fully fund the entire science budget of a mid-sized U.S. state university system for a decade).

The FTC’s complaint is explicit: this was not opportunistic deal-making. GTCR’s own August 2022 investment committee presentation, written before the Biocoat deal even closed, laid out a deliberate strategy for consolidation in the outsourced hydrophilic coatings market. A January 2023 Biocoat board of directors presentation referenced the same strategy. Before targeting Surmodics, GTCR and Biocoat explored acquiring other competitors in the sector. Then in January 2024, they circled back and went after the number one player.

They Called It A “Consolidation Play.” The FTC Calls It Illegal.

The FTC’s complaint describes GTCR’s acquisition strategy as consistent with a plan for an [acquisition strategy described in the investment committee presentation] in the outsourced hydrophilic coatings market. The specific language GTCR used internally to describe this market and their intentions is redacted in the public version of the complaint, but the structure of the plan is documented: buy #2, explore other targets, then acquire #1, and end up controlling the whole thing.

GTCR also did not stop scheming after the Proposed Acquisition was announced. The FTC notes that on June 3, 2024, after the Proposed Acquisition became public, GTCR [took additional actions documented in the complaint but redacted from the public version]. The pattern of behavior before and after the announcement shows a firm treating antitrust law as an inconvenience to be managed, not a line to respect.

If consummated, this deal would hand one private equity firm control over the coatings applied to the medical devices sliding through your arteries. The price they charge for those coatings would have no competitive check. None.

The Non-Financial Ledger: What A Medical Device Monopoly Actually Costs You

The FTC’s complaint is written in the dry, precise language of antitrust law. It talks about HHI scores, market concentration thresholds, and merger efficiencies. What it does not dwell on, but what is clearly implied in every paragraph, is the human cost of allowing one private equity firm to control the coatings applied to the tools doctors use to save lives. The financial harm to corporate customers (the OEMs) is real. But behind those OEMs are patients in hospital beds. Behind every guidewire threaded through a coronary artery is a human being. The price of a coating monopoly is not abstract.

The FTC documents that head-to-head competition between Surmodics and Biocoat has directly driven higher quality coatings, better service, lower prices, and greater innovation. That competition produced tangible, documented improvements in medical device safety and performance. One OEM customer, when it had concerns about the performance of Surmodics’ hydrophilic coating on its device, used Biocoat as leverage. The result, according to the FTC complaint, was a higher quality product from Surmodics at better terms. That is competition working exactly as it should for patients: the threat of losing a customer to a rival forced the supplier to do better. When GTCR consumes both suppliers, that pressure disappears entirely.

The FTC complaint explicitly names the anticipated harms once competition is eliminated: lower quality coatings, diminished service levels, reduced innovation, and higher prices. Each of those four outcomes is a patient safety issue, not just a business inconvenience. Lower coating quality means higher particulate counts, which means more coating particles shed inside patients’ bodies during procedures. Diminished service means smaller medical device startups, which often lack the engineering resources of industry giants, get less technical support when trying to get their devices through FDA approval. Reduced innovation means next-generation coatings take longer to reach the market, and patients who need those improvements wait longer or never see them. Higher prices mean the cost of manufacturing life-saving devices rises, and that cost does not stop at the device maker. It flows downstream to hospitals, to insurers, and ultimately to the patients and families paying out-of-pocket costs, co-pays, and premiums.

There is a specific type of patient harm embedded in the FDA lock-in mechanism that deserves its own accounting. Because the FDA approves the complete medical device, including its specific coating, switching coatings on an approved device requires starting the entire regulatory process over. This means that if GTCR acquires both Surmodics and Biocoat and then decides to raise prices, degrade service, or reduce coating quality on commercialized products, the OEMs using those products are trapped. They cannot easily switch to a competitor because the competitor has been absorbed. They cannot make the coating in-house because the chemistry is too specialized and their existing FDA approval does not cover an in-house formula. They are locked in, potentially for the decade-plus commercial lifetime of each device. Every patient who undergoes a neurovascular, cardiovascular, or peripheral vascular procedure with that device during that entire period would be treated with a product made by a captive supplier that has no competitive reason to maintain performance standards.

The FTC complaint also documents that small startup medical device companies are especially exposed. Startups do not have the resources to develop in-house coatings. They do not have the engineering depth to run their own feasibility testing and optimization. They depend entirely on Surmodics and Biocoat for the technical expertise, regulatory support, and contract coating services that let them bring new devices to market. These startups are the source of medical innovation in interventional medicine: new catheters, new guidewires, next-generation devices for procedures that are becoming standard care. A monopolist controlling the coating supply can demand higher prices and worse terms from these startups, absorb the ones that cannot pay, or simply slow-walk their development support until the startup fails. The cost to patients is measured in medical innovations that never arrive.

Competition between Surmodics and Biocoat also directly drove innovation that already exists in the market. Biocoat hired Surmodics’ former Senior Director of Hydrophilic Technologies and used his expertise to develop Hydak UV, a new UV-cured hydrophilic coating, which launched in 2020 and was approved for use on FDA-cleared devices by 2023. Surmodics, in direct response to the competitive threat from Biocoat’s improving product lineup, developed and released Preside, its next-generation coating, in late 2023. Both of those innovations exist because two companies were fighting for the same customers. When GTCR absorbs both companies, the incentive to innovate collapses into the incentive to extract rent. The patients who would have benefitted from the next round of innovation, the coating that comes after Preside and Hydak UV, may never see it.

Legal Receipts: What The Government Documented, Word For Word

“The Proposed Acquisition may be analyzed in a relevant market that is no broader than outsourced hydrophilic coatings. Specialized third-party hydrophilic coating providers are a distinct, critical, and growing part of the medical device ecosystem.” — FTC Amended Complaint, ¶4, May 14, 2025

“The Proposed Acquisition is presumptively illegal because it would significantly increase concentration in the already highly concentrated outsourced hydrophilic coatings market. The Proposed Acquisition would result in GTCR controlling more than 50 percent of the outsourced hydrophilic coatings market in the United States, well above the threshold to establish a prima facie case that the Proposed Acquisition is unlawful.” — FTC Amended Complaint, ¶6, May 14, 2025

“FDA approval is granted for the complete medical device, not individual components, effectively ‘locking in’ the hydrophilic coating for the medical device’s lifespan.” — FTC Amended Complaint, ¶77, May 14, 2025

“This vigorous head-to-head competition has led both Surmodics and Biocoat to offer higher quality coatings and service, better pricing terms, and more innovative products. The Proposed Acquisition is unlawful because it will eliminate this competition and its attendant benefits, harming OEM customers and, ultimately, patients.” — FTC Amended Complaint, ¶8, May 14, 2025

“There are no countervailing factors sufficient to offset the likelihood of competitive harm from the Proposed Acquisition. The merging parties cannot demonstrate that new entry in the market would be timely, likely, or sufficient to offset these anticompetitive effects. Nor can they show cognizable, verifiable, or merger-specific efficiencies sufficient to offset the likely and substantial competitive harm from the Proposed Acquisition.” — FTC Amended Complaint, ¶9, May 14, 2025

“New coating providers, especially those without existing reputations or relationships, face additional challenges in gaining market traction because OEMs are hesitant to adopt coatings without a proven track record. OEMs prioritize the stability and longevity of their coating providers because they rely on them for extended periods.” — FTC Amended Complaint, ¶79, May 14, 2025

Societal Impact Mapping: Who Gets Hurt When Private Equity Controls Life-Critical Supplies

Public Health

The FTC complaint draws a direct line from this merger to patient harm. Hydrophilic coatings are described as “critical to a device’s safety and performance” and the mechanism by which medical devices avoid causing “abrasions” to “small, sensitive structures, such as blood vessels” inside the human body. The procedures that rely on these coatings include neurovascular surgery (inside the brain), coronary procedures (the heart), peripheral vascular procedures (arteries throughout the body), and structural heart procedures. These are among the most delicate, highest-stakes interventions in modern medicine.

The FTC specifically flags particulate count as a critical safety metric. When a hydrophilic coating sheds particles during use, those particles are released inside the patient’s body. The FDA has been tightening its requirements on particulate counts, meaning regulators already recognize this as an active and serious patient safety concern. The competitive pressure between Surmodics and Biocoat has been a driver of improvement in this metric. A monopolist faces no such pressure. Once the competition is gone, the incentive to push particulate counts lower, to invest in the R&D to make coatings shed less inside people’s bodies, collapses.

The FTC documents that an OEM whose medical device is rejected by the FDA due to poor hydrophilic coating performance “can be set back by millions of dollars and multiple years.” Under a competitive market, coating providers have strong incentives to maintain performance standards to keep OEM customers. Under a monopoly, the calculus changes. GTCR, controlling both Surmodics and Biocoat, could allow service and quality to degrade while OEMs have nowhere else to turn. The patients waiting for FDA-approved devices built on those degraded coatings bear the cost in delayed procedures, longer hospitalizations, and increased risk of procedural complications.

The FTC complaint also notes that demand for outsourced hydrophilic coatings is expected to grow as the FDA implements increasingly stringent coating performance requirements. This is a market expanding in importance at exactly the moment a private equity firm is attempting to lock it up. Future patients, patients who will undergo interventional procedures that do not yet exist as standard of care, are the ultimate population at risk. Their access to safe, innovative, affordable medical devices depends on a competitive coating supply market. GTCR tried to end that competition permanently.

Economic Inequality

The economic harm in this case is concentrated at multiple layers of the supply chain, and each layer ultimately passes costs down to ordinary people. At the top, OEM customers, the companies that build the devices, face higher input costs when a monopolist controls the coating supply. The FTC documents that Surmodics and Biocoat compete aggressively on price and pricing structure, including licensing rates, royalty rates, and per-unit payments that continue for the entire commercial life of a device. A monopolist can raise all of those rates simultaneously with no competitive pressure to hold them down.

Those higher costs flow downstream. Medical device manufacturers charge hospitals more. Hospitals charge insurers more. Insurers raise premiums. Patients pay higher co-pays, face higher out-of-pocket maximums, and see more procedures categorized as elective or non-covered to manage insurer costs. The person least able to absorb these cascading price increases is the uninsured or underinsured patient who needs a neurovascular or cardiovascular procedure. They are the furthest from the boardroom where GTCR’s investment committee wrote its consolidation strategy, and they are the most exposed to its consequences.

Small and startup medical device companies face a particular form of economic extortion under a monopoly structure. The FTC complaint documents that small startups “do not have the resources or time to develop an in-house solution and do not want to jeopardize the launch of the device” by partnering with an unproven coating supplier. They are entirely dependent on the established players. A GTCR-controlled monopoly could extract higher prices, worse licensing terms, and reduced service from these startups, knowing full well that the startups have no viable alternative. Many of those startups represent the next generation of medical innovation. If their economics are crushed by a captive supplier relationship, they do not reach the market, do not attract follow-on investment, and do not deliver their innovations to patients. The concentration of wealth and market power at the top of the supply chain actively suppresses innovation and economic opportunity at every level below it.

The “Cost of A Life” Metric